Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia

Davide Rossi, Lodovico Terzi-Di-Bergamo, Lorenzo De Paoli, Michaela Cerri, Guido Ghilardi, Annalisa Chiarenza, Pietro Bulian, Carlo Visco, Francesca R. Mauro, Fortunato Morabito, Agostino Cortelezzi, Francesco Zaja, Francesco Forconi, Luca Laurenti, Ilaria Del Giudice, Massimo Gentile, Iolanda Vincelli, Marina Motta, Marta Coscia, Gian Matteo RigolinAlessandra Tedeschi, Antonino Neri, Roberto Marasca, Omar Perbellini, Carol Moreno, Giovanni Del Poeta, Massimo Massaia, Pier Luigi Zinzani, Marco Montillo, Antonio Cuneo, Valter Gattei, Robin Foà, Gianluca Gaidano

Research output: Contribution to journalArticle

Abstract

Fludarabine, cyclophosphamide, and rituximab (FCR) has represented a significant treatment advancement in chronic lymphocytic leukemia (CLL). In the new scenario of targeted agents, there is an increasing interest in identifying patients who gain themaximumbenefit from FCR. In this observationalmulticenter retrospective analysis of 404 CLL patients receiving frontline FCR, the combination of three biomarkers that arewidely tested before treatment (IGHV mutation status, 11q deletion and 17p deletion; available in 80% of the study cohort) allowed to identify a very low-risk category of patients carrying mutated IGHV genes but neither 11q or 17p deletion that accounted for 28%of all cases. The majority of very low-risk patients (71%) remainedfreeofprogression after treatmentandtheir hazard of relapsedecreased after 4 years fromFCR.Thelife expectancy of very low-risk patients (91% at 5 years) was superimposable to that observed in the matched normal general population, indicating that neither the disease nor complications of its treatment affected survival in this favorable CLL group. These findings need a prospective validation and may be helpful for the design of clinical trials aimed at comparing FCR to new targeted treatments of CLL, and, possibly, for optimized disease management.

Original languageEnglish
Pages (from-to)1921-1924
Number of pages4
JournalBlood
Volume126
Issue number16
DOIs
Publication statusPublished - Oct 15 2015

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia'. Together they form a unique fingerprint.

  • Cite this

    Rossi, D., Terzi-Di-Bergamo, L., De Paoli, L., Cerri, M., Ghilardi, G., Chiarenza, A., Bulian, P., Visco, C., Mauro, F. R., Morabito, F., Cortelezzi, A., Zaja, F., Forconi, F., Laurenti, L., Del Giudice, I., Gentile, M., Vincelli, I., Motta, M., Coscia, M., ... Gaidano, G. (2015). Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood, 126(16), 1921-1924. https://doi.org/10.1182/blood-2015-05-647925